Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Rona Reibis, Christina Jannowitz, Martin Halle, David Pittrow, Anselm Gitt & Heinz Völler. (2015) Management and outcomes of patients with reduced ejection fraction after acute myocardial infarction in cardiac rehabilitation centers. Current Medical Research and Opinion 31:2, pages 211-219.
Read now
Read now
Sheila A Doggrell. (2013) Comment on: Clinical benefits of ezetimibe: absence of proof is just that. Expert Opinion on Pharmacotherapy 14:18, pages 2611-2613.
Read now
Read now
Roberto Lozano, Reyes Marin, M-Jesus Santacruz & Isabel Freire. (2013) Ezetimibe–Simvastatin, a pharmacodynamic interaction?. Expert Opinion on Pharmacotherapy 14:3, pages 359-360.
Read now
Read now
John David Spence. (2012) Letter to the Editor: The ezetimibe ‘controversy' is a misunderstanding. Expert Opinion on Pharmacotherapy 13:17, pages 2579-2580.
Read now
Read now
Ioanna Gouni-Berthold, Dimitri P. Mikhailidis & Manfredi Rizzo. (2012) Clinical benefits of ezetimibe use: is absence of proof, proof of absence?. Expert Opinion on Pharmacotherapy 13:14, pages 1985-1988.
Read now
Read now
Articles from other publishers (5)
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
285
315
.
Alessandro Battaggia, Alberto Donzelli, Maria Font, Davide Molteni & Antonio Galvano. (2015) Clinical Efficacy and Safety of Ezetimibe on Major Cardiovascular Endpoints: Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLOS ONE 10:4, pages e0124587.
Crossref
Crossref
Huseyin NaciJohn P.A. Ioannidis. (2015) How Good Is “Evidence” from Clinical Studies of Drug Effects and Why Might Such Evidence Fail in the Prediction of the Clinical Utility of Drugs?. Annual Review of Pharmacology and Toxicology 55:1, pages 169-189.
Crossref
Crossref
Barak Zafrir & Mohit Jain. (2014) Lipid-lowering Therapies, Glucose Control and Incident Diabetes: Evidence, Mechanisms and Clinical Implications. Cardiovascular Drugs and Therapy 28:4, pages 361-377.
Crossref
Crossref
Michael J. Sorich, Michael D. Wiese, Rebekah L. O’Shea & Brita Pekarsky. (2013) Review of the Cost Effectiveness of Pharmacogenetic-Guided Treatment of Hypercholesterolaemia. PharmacoEconomics 31:5, pages 377-391.
Crossref
Crossref